NASDAQ:GOVX - Nasdaq - US3736786068 - Common Stock - Currency: USD
1.71
-0.12 (-6.56%)
The current stock price of GOVX is 1.71 USD. In the past year, price decreased by -19.72%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 25.15 | 15.34B |
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
GEOVAX LABS INC
1900 Lake Park Drive, Suite 380
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Company Website: https://www.geovax.com/
Phone: 16783847220
The current stock price of GOVX is 1.71 USD. The price decreased by -6.56% in the last trading session.
The exchange symbol of GEOVAX LABS INC is GOVX and it is listed on the Nasdaq exchange.
GOVX stock is listed on the Nasdaq exchange.
11 analysts have analysed GOVX and the average price target is 14.89 USD. This implies a price increase of 770.88% is expected in the next year compared to the current price of 1.71. Check the GEOVAX LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GEOVAX LABS INC (GOVX) has a market capitalization of 16.14M USD. This makes GOVX a Nano Cap stock.
GEOVAX LABS INC (GOVX) currently has 17 employees.
GEOVAX LABS INC (GOVX) has a support level at 1.45 and a resistance level at 1.84. Check the full technical report for a detailed analysis of GOVX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GOVX does not pay a dividend.
GEOVAX LABS INC (GOVX) will report earnings on 2025-05-12.
GEOVAX LABS INC (GOVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.97).
The outstanding short interest for GEOVAX LABS INC (GOVX) is 8.12% of its float. Check the ownership tab for more information on the GOVX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to GOVX. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -18.97. The EPS decreased by -42.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -218.88% | ||
ROE | -286.01% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to GOVX. The Buy consensus is the average rating of analysts ratings from 11 analysts.